Abstract
There are no data focusing on the safety of overdose of ampicillin and pyridium during pregnancy. This study aims to report the outcome of a pregnant woman with an acute overdose of oral ampicillin+pyridium in the 14th week of pregnancy. A 27-year-old woman was referred to Teratology Information Service with a suicide history of ingesting 28 ampicillin+pyridium (500+50 mg) tablets. A structured, evidence-based counseling regarding her exposure to overdosing was provided, and she decided to continue her pregnancy. She gave birth to a baby in the 38th gestational week with fetal growth restriction (FGR), with no major congenital malformations and/or deformations. The follow-up of the infant in the 14th month of her life revealed normal physical and neurodevelopmental findings. Because the mother had no major risk factors and exposure of experimental animals to this overdosage have yielded comparable results, and the FGR in this case may be attributed to medication exposure.
Highlights
Ampicillin is a widely prescribed aminopenicillin antibiotic which inhibits bacterial cell-wall synthesis and pyridium is a urinary tract analgesic, which is used to relieve pain in urinary tract infections
A 27-year-old, 14-week pregnant women referred to the Izmir Tepecik-TERAFAR Teratology Information Service to receive counseling regarding medication exposure during her pregnancy
The authors described the outcome of a pregnant patient who was exposed to a high dose of ampicillin and pyridium during the second trimester of her pregnancy
Summary
Pregnancy outcome following intentional ampicillin and pyridium overdose during the second trimester: a case report. Summary There are no data focusing on the safety of overdose of ampicillin and pyridium during pregnancy. This study aims to report the outcome of a pregnant woman with an acute overdose of oral ampicillin+pyridium in the 14th week of pregnancy. A 27-year-old woman was referred to Teratology Information Service with a suicide history of ingesting 28 ampicillin+pyridium (500+50 mg) tablets. A structured, evidence-based counseling regarding her exposure to overdosing was provided, and she decided to continue her pregnancy. She gave birth to a baby in the 38th gestational week with fetal growth restriction (FGR), with no major congenital malformations and/or deformations.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical and Experimental Obstetrics & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
